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Cystic fibrosis (CF) patients have chronic airway infection and frequent exposure to
antibiotics, which often leads to the emergence of resistant organisms. Achromobacter
xylosoxidans is a new emergent pathogen in CF spectrum. From 2005 to 2010 we had an
outbreak in A. xylosoxidans prevalence in our CF center, thus, the present study was
aimed at deeply investigating virulence traits of A. xylosoxidans strains isolated from
infected CF patients. To this purpose, we assessed A. xylosoxidans genome variability by
randomly amplified polymorphic DNA (RAPD), biofilm production, antibiotic resistances,
and motility. All A. xylosoxidans strains resulted to be biofilm producers, and were
resistant to antibiotics usually employed in CF treatment. Hodge Test showed the ability
to produce carbapenemase in some strains. Strains who were resistant to β-lactamics
antibiotics, showed the specific band related to metal β-lactamase (blaIMP-1), and some of
them showed to possess the integron1. Around 81% of A. xylosoxidans strains were
motile. Multivariate analysis showed that RAPD profiles were able to predict Forced
Expiratory Volume (FEV1%) and biofilm classes. A significant prevalence of strong biofilm
producers strains was found in CF patients with severely impaired lung functions (FEV1%
class 1). The outbreak we had in our center (prevalence from 8.9 to 16%) could be
explained by an enhanced adaptation of A. xylosoxidans in the nosocomial environment,
despite of aggressive antibiotic regimens that CF patients usually undergo.
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INTRODUCTION
In sputa of patients with Cystic fibrosis (CF), the Gram-negative
Pseudomonas aeruginosa and the Gram-positive Staphylococcus
aureus are the most frequently found pathogens. Recently, new
bacterial species have also emerged, such as Burkholderia cepa-
cia complex, Stenotrophomonas maltophilia, and Achromobacter
xylosoxidans (Dakin et al., 2002; Rajan and Saiman, 2002; Saiman
and Siegel, 2004; Vonberg and Gastmeier, 2005; Spicuzza et al.,
2009; Hansen et al., 2010). A. xylosoxidans is an environmental
Gram-negative bacillus with harmful properties in immuno-
compromised hosts. It is difficult to be correctly identified, and
suffers from a confusing nomenclature (Liu et al., 2002; Hauser
et al., 2011). A. xylosoxidans is increasingly being isolated from
sputa of CF patients (Zemel et al., 2000; Liu et al., 2002): its
current prevalence ranges from 2 to 11% (Tan et al., 2002;
Raso et al., 2008; Magni et al., 2010; Lambiase et al., 2011).
Recently, a Brazilian study reported a prevalence of 21.8% (Pereira
et al., 2011). Infection is frequently transient, although approxi-
mately 2.3% of CF patients are chronically infected (Tan et al.,
2002). Relatively little is known about the clinical significance
of A. xylosoxidans in CF patients, but it was found that infec-
tion occurs in CF patients with advanced lung disease (Lambiase
et al., 2011): thus, additional studies are necessary to deter-
mine the aetio-pathological role A. xylosoxidans in CF. To this
end, we decided to study some characteristics of A. xylosox-
idans in selected strains isolated from CF patients, such as:
genomic variability, biofilm production, antibiotic resistance, and
motility. The last three bacterial features are considered impor-
tant prerequisites for in vivo colonization and infection, and
recent evidence report on their interdependence (Molin and
Tolker-Nielsen, 2003; Hoffman et al., 2005; Shrout et al., 2011;
Boles and Horswill, 2012). During chronic lung infection of
CF patients, bacteria can survive under the challenging selec-
tive pressure imposed by both immune system and antibiotic
regimens, developing both antibiotic resistances and biofilm for-
mation (Macfarlane et al., 2011; Sibley and Surette, 2011; Sibley
et al., 2011; Bragonzi et al., 2012). Furthermore, many bacterial
species become highly motile thanks to enhanced production of
flagella and pili (Henrichsen, 1983; Jarrell and McBride, 2008),
also within established biofilms (Houry et al., 2012), increasing
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the efficiency in nutrient acquisition, the ability in avoiding
toxic compounds, and the colonization of new available patches
(Amiel et al., 2010; Sibley and Surette, 2011). Due to the dou-
bled prevalence of CF patients colonized by A. xylosoxidans in
our CF center, the present study was aimed at characterizing 57
strains of A. xylosoxidans isolated from CF patients and non-CF
patients by: (i) genomic variability assessed by RAPD; (ii) ability
to produce biofilm on abiotic surface; (iii) antibiotic resistance
patterns; (iv) motility assay. Multivariate analysis was employed
to cross-correlate all collected data.
MATERIALS AND METHODS
PATIENTS
From January 2008 to January 2010, our laboratory isolated 225
strains of A. xylosoxidans from respiratory samples (i.e., sputum
and tracheal aspirated) of 80 CF patients attending the CF Centre
of the Pediatric Department of Policlinico Umberto I of Rome
and from 5 non-CF patients. For the present study, we selected
52 strains from 34 CF patients, taken within the aforementioned
group of 80, for whom A. xylosoxidans strains were isolated more
than once. In addition, five strains were isolated from 4 non-
CF patients: three strains from respiratory samples of 2 patients
with a genetic respiratory disorder (Kartagener syndrome), and
other two strains from 2 blood samples. Thus, the total num-
ber of selected A. xylosoxidans strains for this study was 57 from
overall 38 patients. We divided the 34 CF selected patients into
the following three Forced Expiratory Volume (FEV1%) classes
(following the European Respiratory Society’s criteria): class 3,
mild obstruction or normal (≥70%); class 2, moderate obstruc-
tion (>40 and<70%); and class 1, severe obstruction (≤40%). A
further subdivision was based on the chronic or intermittent pres-
ence of A. xylosoxidans. Chronicity was considered when there
was a sputum culture positive for A. xylosoxidans in at least three
occasions over a 6-month period, as previously suggested (Tan
et al., 2002). In Table 1 are summarized patients’ demographics
and clinical features. All patients were involved in the study after
providing written consent. The study protocol was approved by
the Committee on Ethical Practice of the Policlinico Umberto I,
Rome, Italy.
MICROBIAL IDENTIFICATION
API 20NE system (bioMérieux, Marcy l’Etoile, France) and auto-
mated Vitek2 system (bioMérieux, Marcy l’Etoile, France) were
used for strains identification. Oxidase activity was checked
with dimethyl-paraphenylenediamine disks (bioMérieux, Marcy
l’Etoile, France). Results obtained from API 20NE tests and oxi-
dase reactions were further interpreted with the Apilab Plus
software package (bioMérieux, Marcy l’Etoile, France). In order
to avoid misidentification of Gram negative bacilli, isolated from
CF patients, we performed species-specific PCR for all A. xylosox-
idans strains. Collected strains were cryopreserved at −80◦C
before use. Antibiotic resistances assays for all A. xylosoxidans
strains were provided by automated Vitek2 system.
DNA EXTRACTION
A. xylosoxidans DNA extraction was performed by use of a
Wizard genomic DNA purification kit (Promega Corporation,
Madison, WI) following manufacturer’s instructions. DNA was
finally quantified by spectrophotometer at 260 nm, and its quality
assayed by 260/280 nm ratio.
SPECIES-SPECIFIC PCR ASSAY
Species-specific PCR was performed as described elsewhere
(Hogardt et al., 2007). Negative and positive control PCRs were
employed for every experiment. PCR products were visualized by
electrophoresis in a 2% agarose gel (Invitrogen Corporation, CA),
stained with ethidium bromide (EtBr; Invitrogen Corporation),
and captured with a DigiDoc-It (UVP, Cambridge, United
Kingdom) photographic system. Bands of 163 bp were considered
positive for A. xylosoxidans identification.
RAPD TYPING
The RAPD amplification mixture and cycling conditions were
described elsewhere (Lambiase et al., 2006). The primer used was
the 270 (5′-TGCGCGCGGG-3′). RAPD products were separated
by electrophoresis in 1.5% agarose gel (Invitrogen Corporation,
CA). Molecular size markers (Invitrogen Corporation) and neg-
ative control were included in all gels. Gels were stained with
EtBr (at 0.5μM) (Invitrogen Corporation) and captured with a
DigiDoc-It (UVP) photographic system.
BIOFILM PRODUCTION ASSAY
Overnight cultures of A. xylosoxidans in Trypticase Soy Broth
(Becton Dickinson) at 37◦C in dynamic conditions (90 rpm),
were diluted into fresh TSB to reach OD550 = 1 (corresponding
to 1 × 109 CFU/ml). After diluting 1:100 the bacterial culture,
200μl were used to inoculate sterile flat-bottom polystyrene tis-
sue culture 96-wells plates, followed by a 48 h incubation at
37◦C. Non-adherent bacteria were removed by washing three
times with sterile Phosphate Buffered Saline (PBS).Wells were
stained at room temperature for 5min with 200μl of 1% Crystal
Violet solution, then rinsed with distilled water and dried at
37◦C for 30min. Stained biofilm were dissolved adding 250μl
of 33% glacial acetic acid for 15min. The optical density (OD)
of each well was measured at 570 nm using a microtiter-plate
reader (Multiskan EX, Thermo Scientific, Massachusetts, USA).
A. xylosoxidans strains were divided following Stepanovic method
(Stepanovic et al., 2007), into different biofilm producers classes,
named: N, no biofilm producer; W, weak biofilm producer; M,
moderate biofilm producer; and S, strong biofilm producer.
MOTILITY ASSAY
Swimming assay was performed in “Swim plates” [tryptone broth
(10 g/l tryptone (Difco)-5 g/l NaCl) containing 0.3% (wt/vol)
agarose (GIBCO/BRL)]. LB agar Overnight culture of isolated
strains identified as A. xylosoxidans, were used to inoculate Swim
plates, and incubated at 30◦C for 12–14 h (Rashid et al., 2000).
Diameter of resulting concentric ring, expressed in millimetres,
was used to define the motility of a specific A. xylosoxidans
strain.
PCR DETECTIONS OF RESISTANCE DETERMINANTS
The presence of Class 1 Integron was tested by PCR, by means
of specific primers: 5′-CS (GGC ATC CAA GCA GCA AGC) and
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Table 1 | Patients’ demographics and strains characteristics.
Patient Age FEV1% Weight Height BMI Strainc Biofilm Chronicity ResistANcese Swimming
(year) class (kg) (m) class (mm)
1 20 2 48.0 1.70 16.6 129 M 1 ATM, GM, NN 17.7
1 47.0 1.70 16.2 157 W 1 ATM, GM, NN 23.7
2 (K)a 42 nab 76.5 1.82 23.1 232 S 1 AN, ATM, FEP, CIP, GM, MER, PIP,
TIM, NN
13.0
3 56 2 80.0 1.65 29.4 66 W 0 AN, ATM, FEP, CIP, GM 26.3
4 6 na 19.2 1.10 15.9 180 M 1 AN, ATM, FEP, CIP, GM, NN 24.3
5 44 1 60.0 1.74 19.8 128 S 1 AN, ATM, FEP, CIP, CS, GM, MN, NN na
2 60.0 1.74 19.8 147 W 1 AN, FEP, CIP, GM, NN 22.7
3 60.0 1.74 19.8 248 S 1 AN, ATM, FEP, CIP, GM, NN na
6 36 1 41.0 1.55 17.1 35 Md 0 AN, ATM, FEP, CIP, GM, NN 35.7
2 50.0 1.55 20.8 241 S 0 ATM, FEP, CIP, GM, MER, MN, NN 28.3
7 34 1 44.0 1.65 16.2 145 Sd 0 AN, ATM, FEP, CIP, CS, GM, MN, NN na
8 32 3 62.8 1.69 21.9 53 W 1 AN, ATM, GM 52.3
2 61.0 1.69 21.3 228 S 1 AN, ATM, FEP, CIP, GM, PIP, NN na
2 61.0 1.69 21.3 229 W 1 AN, ATM, FEP, CIP, GM, MN, NN 23.7
9 23 1 45.0 1.78 14.2 209g S 1 ATM, MER 31.0
1 45.0 1.78 14.2 209p S 1 FEP, CIP, MER 28.0
10 15 3 40.8 1.51 17.9 144 S 1 AN, ATM, FEP, GM, PIP, NN 29.3
11 48 1 52.0 1.63 19.6 4 S 1 AN, ATM, FEP, CAZ, CIP, GM, IPM,
MER, PIP, TIM, NN
23.7
na 55.0 1.64 20.5 276 S 1 AN, ATM, FEP, CIP, GM, NN 56.3
na 55.0 1.64 20.4 277 S 1 AN, ATM, FEP, CIP, GM, NN 52.3
12 35 1 68.4 1.72 23.1 77 M 0 AN, ATM, FEP, CIP, GM, NN 39.7
1 68.4 1.72 23.1 287 M 0 AN, ATM, FEP, CIP, CS, GM, MN, NN 50.3
13 5 na 21.7 1.10 17.8 162 W 0 AN, ATM, CS, GM 52.3
14 19 2 58.3 1.70 20.2 84 S 1 ATM, GM na
15 7 3 19.6 1.20 13.6 101p M 0 AN, ATM, CS, GM, NN 9.7
16 23 1 40.0 1.56 16.4 266 S 1 GM, NN 14.7
1 40.0 1.56 16.4 278 S 1 AN, GM, NN 14.0
17 24 1 52.0 1.61 20.1 252 S 0 AN, ATM, CIP, GM, MN, NN na
18 21 2 60.0 1.67 21.5 222 W 0 ATM, CIP 56.3
19 34 1 na na na 116 S 1 AN, ATM, CIP, GM, NN 23.0
na 48.5 1.70 16.8 267 S 1 AN, ATM, FEP, CIP, CS, GM, NN 21.3
20 8 2 21.3 1.21 14.5 207 M 0 GM 30.7
21 37 2 58.0 1.67 20.8 251 S 1 AN, ATM, FEP, CAZ, CIP, GM, IPM,
TIM, NN
61.7
22 6 3 23.0 1.23 15.2 153 S 0 – na
23 (B)a 61 na na na na 291 S 0 ATM, GM 31.0
24 (B)a 51 na na na na 230 S 0 AN, ATM, CS, GM 43.7
25 22 2 68.0 1.88 19.2 167p S 0 AN, ATM, FEP, CIP, GM, MN, PIP, NN na
26 21 3 53.0 1.68 18.8 226 M 1 AN, ATM, FEP, CIP, GM, MN, NN 42.7
27 24 3 40.0 1.51 17.5 133 S 0 AN, ATM, FEP, CIP, CS, GM, NN na
2 40.0 1.51 17.5 231 M 0 AN, ATM, FEP, CS, GM 9.3
28 26 1 48.0 1.56 19.7 68 S 0 AN, ATM, GM, NN 35.0
29 22 3 67.0 1.82 20.2 247 S 0 ATM 40.3
30 21 3 62.6 1.73 20.9 225 S 0 AN, ATM, FEP, CIP, GM, NN 55.7
31 44 1 49.0 1.56 20.1 24 S 0 ATM, GM, MN, NN 20.3
32 14 3 56.0 1.60 21.8 49 M 1 AN, ATM, GM 54.0
3 56.5 1.60 22.1 50 M 1 ATM 53.0
33 43 2 52.0 1.67 18.6 275 M 1 AN, ATM, FEP, CIP, GM, NN 8.3
34 1 na 8.6 0.72 16.3 215 M 0 ATM, NN 21.7
(Continued)
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Table 1 | Continued
Patient Age FEV1% Weight Height BMI Strainc Biofilm Chronicity ResistANcese Swimming
(year) class (kg) (m) class (mm)
35 27 2 55.0 1.61 21.2 90 M 0 AN, ATM, FEP, CIP, CS, GM, NN 28.3
1 61.6 1.60 24.1 237 S 0 AN, ATM, FEP, CIP, GM, NN 50.3
36 (K) 34 na 59.0 1.63 22.2 175 S 0 AN,. ATM, FEP, CIP, GM, NN 33.7
37 36 1 49.6 1.61 19.1 213 S 1 AN, FEP, CIP, GM, MN 11.7
38 (K) 26 na na na na 67 S 0 AN, ATM, GM 43.0
39 30 3 52.7 1.65 19.3 249 M 1 AN, FEP, CS, IPM, MER, PIP 22.7
3 52.7 1.65 19.3 250 S 1 AN, ATM, FEP, CIP, GM, IPM, TIM,
NN
na
3 54.9 1.65 20.2 218g M 1 AN, ATM, FEP, CIP, GM, NN 55.0
3 54.9 1.65 20.2 218p S 1 FEP, CIP, IPM, MN na
aK, Kartagener syndrome; B, blood culture.
bna, not available.
cLetters g and p stand for different morphologies of the A. xylosoxidans colony grown on BCSA.
d Biofilm class was assessed after PLS-DA model.
eResistances were determined by automated Vitek 2 system: ATM, aztreonam; GM, gentamicin; AN, amikacin; NN, tobramycin; FEP, cefepime; CIP, ciprofloxacin;
CS, colistin; MN, minociclin; MER, meropenem; PIP, piperacillin; IPM, imipenem; TIM, ticarcillin-clavulanic acid; CAZ, ceftazidime; and TZP, piperacillin + tazobactam.
3′-CS (AAA GCA GAC TTG ACC TGA) (Levesque et al., 1995;
Neuwirth et al., 2006). Carbapenemase determinants blaIMP,
blaVIM, and β-lactamase determinants blaVEB plus blaOXA-1
were also assayed by PCR. Primer used were: IMP-1 F (5′CAT
GGT TTG GTG GTT CTT GT 3′) and IMP-1 R (5′ATA ATT
TGG CGG ACT TTG GC 3′) for blaIMP (Yum et al., 2002);
VIM-F (5′-AGT GGT GAG TATCCG ACA G-3′) and VIM-R
(5′-ATG AAA GTG CGTGGA GAC-3′) for blaVIM1 (Tsakris
et al., 2000); VIM-2A (5′-ATGTTCAAACTTTTGAGTAGTAAG-
3′) and VIM-2B (5′CTACTCAACGACTGAGCG-3′) for blaVIM-
2-like genes (Poirel et al., 2000); VEB-1 F (5′ CCA GAT AGG
AGT ACA GAC 3′) and VEB-1 R (5′ GAC TCT GCA ACA
AAT ACG C 3′) for blaVEB1 (Neuwirth et al., 2006); OXA-
1 F (5′CTT GAT TGA AGG GTT GGG CG-3′) and OXA-1 R
(5′AGCCGT TAA AAT TAAGCCC-3′) for blaOXA-1 (Shin et al.,
2005).
DATA ANALYSIS
Agglomerative hierarchical classification (AHC)
AHC, an unsupervised method, was performed on RAPD pro-
files by means of a binary matrix generated by the pres-
ence/absence of RAPD bands, using Doc-It LS software (UVP),
and the subsequent dendrogram was generated with XLStat 7.5
(Addinsoft), using a Euclidean distance dissimilarity matrix and
the agglomeration method of Ward.
Factorial Discriminant Analysis (FDA)
FDA, a supervised method closely linked to multivariate analy-
sis of variance, was employed by means of XLStat 7.5 software
(Addinsoft). Explanatory variables were automatically verified to
be linearly independent by calculating the multiple correlation of
each variable with all the others. Fisher’s test was used to compare
patients’ clinical features or characteristics of selected A. xylosox-
idans strains with RAPD profiles: a P value less than or equal to
0.05 was considered statistically significant.
RESULTS
ACHROMOBACTER XYLOSOXIDANS ISOLATES
Overall 39 patients referring to the Regional CF Centre,
“Policlinico Umberto I” hospital (Rome), were enrolled. Thirty-
four above the 39 patients were affected by CF, while the remain-
ing non-CF subjects had a different disease (three patients with
Kartagener syndrome, that involves an impairment in epithe-
lial cilia movement, and other two patients from an oncologic
unit). Patients with CF and Kartagener syndrome gave sputa
samples, while subjects from oncologic unit gave blood sam-
ples. All CF patients were not permanently convalescing at the
Policlinico Umberto I hospital, but underwent a visit each 6
months, or when specifically required by the physician. Patients’
antibiotic treatments were as follows (taking into considera-
tion the closer to A. xylosoxidans strains isolation from each CF
patient): colimycin 41.18% (14/34), sulfametoxazole + trimetho-
prim 17.65% (6/34), tobramycin 11.76% (4/34), amoxicillin +
clavulanic acid 8.82% (3/34), levofloxacin 8.82% (3/34), amikacin
5.88% (2/52), ceftriaxone 2.94% (1/34), linezolid 2.94% (1/34).
All CF patients went through aforementioned antibiotic treat-
ments for a period of 6 months before A. xylosoxidans sampling
under these conditions: colimycin aerosolized 2 flasks/day every
2 days, sulfametoxazole + trimethoprim orally provided every 2
days, tobramycin aerosolized 300mg/day, amoxicillin + clavu-
lanic acid orally provided every 2 days, levofloxacin provided
intravenously 300mg/day, amikacin aerosolized 1 flask/day, cef-
triaxone provided intravenously 1 dose/day, linezolid orally pro-
vided every 2 days. Patients’ demographics, along with number
and characteristics of A. xylosoxidans isolates, were reported in
Table 1. The isolation range was 1–4 bacterial strains per patient,
with a total of 57A. xylosoxidans strains. At the same time of isola-
tion, data about the Forced Expiratory Value (FEV), expressed as
FEV1%, and the Body Mass Index (BMI), were collected. In the
present study, spanning from January 2008 to January 2010, we
had 80 patients A. xylosoxidans-positive patients above a total of
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500, with a prevalence of 16%: 34/80 were chronically infected,
and we were able to isolate 225 strains. In respect to our pre-
vious study (Magni et al., 2010), we had a significantly higher
prevalence of A. xylosoxidans-positive patients: from 8.9 to 16%
(χ2 = 10.18, P = 0.0014).
RAPD-PCR
The 57 strains of A. xylosoxidans were characterized for their
genomic asset by the Randomly Amplified Polymorphic DNA
(RAPD) technique, useful to look for genetic relationships among
the isolated strains and for discerning strains within a species. In
Figure 1 was reported the dendrogram obtained by Ascendent
Hierarchical Clusterization (AHC), a non-supervised statistical
method to ascertain genomic relatedness among RAPD profiles
obtained. The dendrogram showed two major clusters (A and B):
the first cluster (A) grouped 29/57 A. xylosoxidans isolates, while
the second one (B) grouped 28/57 bacterial strains (Figure 1).
Intra-cluster mean similarity was calculated by Dice index, as
described in Materials and Methods, and gave a result of 45.9 ±
0.8% for cluster A, while it was 41.7 ± 0.8% for cluster B, and this
difference was significant (Mann-Whitney, P = 0.00078).
BIOFILM PRODUCTION
In our assay conditions, all strains were able to produce biofilm on
abiotic surface (96-well plate) (Table 1). On the basis of biofilm
amount produced, assessed at OD570 accordingly to Stepanovic
(Stepanovic et al., 2007), A. xylosoxidans strains were divided into
three different groups: strong (S), moderate (M), and weak (W).
As reported in Table 1, 33/57 (57.9%) strains were strong biofilm
producers, 15/57 (26.3%) strains felt into moderate class, while
7/57 (12.3%) strains were weak producers. Two strains above 57
(3.5%), namely 35 and 145, showed OD590 values intermediate
between strong and moderate produces. Those strains were con-
sequently placed in the class moderate and strong, respectively,
on the basis of their RAPD profiles (see results of statistical
correlations).
MOTILITY ASSAY
Forty-six above 57 A. xylosoxidans strains (80.7%) showed a
swimming phenotype (Table 1), with the formation of a concen-
tric ring with different diameters, expressed inmillimetres. Eleven
A. xylosoxidans isolates resulted negative for swimming motil-
ity. No swarming as well as no twitching phenotype were found
among the isolated strains of A. xylosoxidans (data not shown).
ANTIBIOTIC RESISTANCE PHENOTYPE
All 57 A. xylosoxidans isolates were tested for 14 antibiotic resis-
tances by means of Vitek2 instrument. Results showed (Figure 2)
high frequency of resistances to aztreonam (84%), gentamicin
(84%), amikacin (75%), tobramycin (73%), cefepime (60%) e
ciprofloxacin (60%). Hodge Test showed that 2/11 of the car-
bapenem resistant strains were able to produce carbapenemase.
3/57 strains resistant to β-lactam antibiotics showed to possess
the specific band of the integron1, and 7 the specific band related
to metal β-lactamase (blaIMP-1). Of these last 7 strains, three
showed to possess the specific band of the integron1 meropenem
(MER), piperacillin (PIP), imipenem (IPM), ticarcillin clavu-
lanate (TIM), ceftazidime (CAZ). Taking into consideration the
antibiotic exposure of the 52 selected A. xylosoxidans strains
among CF patients, we found these percentages of prevalence:
Amoxicillin + clavulanic acid 9.62% (5/52), levofloxacin 9.62%
(5/52), ceftriaxone 3.85% (2/52), tobramycin 11.54% (6/52),
colimycin 38.46% (20/52), linezolid 3.85% (2/52), sulfametoxa-
zole + trimethoprim 19.23% (10/52), amikacin 3.85% (2/52).
DATA CORRELATIONS
RAPD—FEV1%
In order to confirm the results already obtained in a previous our
study (Magni et al., 2010) we performed a correlation analysis
between RAPD profiles of the new 57 A. xylosoxidans strains and
patients’ FEV1% classes. A multivariate statistical approach, per-
formed with Factorial Discriminant Analysis (FDA) algorithm,
showed a separation between the FEV1% classes (Figure 3), with
FIGURE 1 | Ascendent Hierarchical Clusterization (AHC). A dendrogram
based on RAPD profiles of A. xylosoxidans strains was generated by means
of inverse Euclidean distance dissimilarity matrix and agglomeration method
of Ward. Two clusters are visible (A and B) based upon a threshold set at
28% of similarity. No known variable was responsible in defining such a
cluster formation (for all variables, P > 0.05).
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FIGURE 2 | Distribution of antibiotic resistances among A.
xylosoxidans isolates. Fourteen antibiotics (x axis) were tested with Vitek
2 instrument: ATM, aztreonam; GM, gentamicin; AN, amikacin; NN,
tobramycin; FEP, cefepime; CIP, ciprofloxacin; CS, colistin; MN, minociclin;
MER, meropenem; PIP, piperacillin; IPM, imipenem; TIM, ticarcillin
clavulanate; CAZ, ceftazidime; and TZP, piperacillin+tazobactam. On y axis
is the fraction of isolates normalized to one. R, resistant; I, intermediate; S,
susceptible; ND, indeterminate.
FIGURE 3 | A. xylosoxidans RAPD profiles grouped by FEV1% class.
The overall data variation was described by the factorial axes t[1] and t[2].
The predictability of the model, in dividing FEV1% classes, was 84.62%
(Fisher’s P = 5.2∗10−10).
a model predictability of 84.62% (Fisher’s P = 5.2∗10−10). The
analysis correctly classified 9/12 (75.0%) of A. xylosoxidans strains
isolated from CF patients with predicted FEV1% class 1, 14/15
(93.3%) of the strains isolated from CF patients with predicted
FEV1% classes 3, and 10/12 (83.3%) of the strains isolated from
FIGURE 4 | A. xylosoxidans RAPD profiles grouped by biofilm classes.
The overall data variation was described by the factorial axes t[1] and t[2].
The predictability of the model, in dividing biofilm classes, was 85.45%
(Fisher’s P = 5.4∗10−11).
CF patients with predicted FEV1% classes 2. Eighteen A. xylosoxi-
dans strains with no predicted FEV1% class were classified among
the three FEV1% classes on the basis of their RAPD profiles: 4 to
class 1, 7 to class 2, and 7 to class 3. The FEV1% class assignment
of these last 18 strains were in agreement with the clinical status
of corresponding CF patients, as assessed by pediatric physicians.
RAPD—Biofilm
The same multivariate statistical approach of PLS-DA was
employed to correlate A. xylosoxidans strains RAPD profiles and
corresponding biofilm classes. The model showed a separation
between the biofilm classes (Figure 4), with amodel predictability
of 85.45% (Fisher’s P = 5.4∗10−11). The analysis correctly clas-
sified 31/33 (93.9%) of strong biofilm producers, 10/15 (66.7%)
of medium one, and 6/7 (85.7%) of weak biofilm producers.
Two A. xylosoxidans strains without biofilm classification were
classified upon their RAPD profiles in this way: one to strong
class, and one to weak class. Furthermore, we studied the dis-
tribution of A. xylosoxidans strains, in relation to their biofilm
production ability, between FEV1% classes. A significant preva-
lence of strong biofilm producers strains was found in FEV1%
class 1 CF patients (FEV1% class 1 vs. FEV1% class 2, P = 0.0007,
χ2 = 11.44; FEV1% class 1 vs. FEV1% class 3, P = 0.0046, χ2 =
8.02) (Table 2). No difference was found in the mean number of
resistance traits among strains colonizing CF patients with dif-
ferent FEV1% value (data not shown). Similarly, no differences
were found comparing mean number of resistance traits and
biofilm producing ability among strains colonizing CF patients
in a chronic or intermittent way (data not shown).
DISCUSSION
In a previous paper (Magni et al., 2010) we showed an A. xylosox-
idans prevalence of 8.9% in our Regional CF center, referred to a
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Table 2 | Distribution of collected strains among biofilm and FEV1%
classes.
Biofilm class
FEV1% class S (n = 33) M (m = 17) W (n = 7)
1 14 5 1
2 6 4 4
3 8 4 1
0 5 4 1
time window from January 2005 to January 2007. In that paper
we reported that above overall 450 patients, 40 were affected
by A. xylosoxidans, 16 were chronically infected, and we iso-
lated 106 strains. In the present study, spanning from January
2008 to January 2010, we found an almost doubled prevalence
of A. xylosoxidans-positive patients (16%), meaning a possible
outbreak in our center. Due to the doubled prevalence found,
we focused our attention on well-known virulence traits able to
enhance bacterial colonization. It was proposed how biofilm for-
mation, antibiotic resistance acquisition, and motility could be
interdependent (Molin and Tolker-Nielsen, 2003; Hoffman et al.,
2005), and recent evidence support such hypothesis (Shrout et al.,
2011; Boles and Horswill, 2012). We studied the abovementioned
virulence factors in 57 CF and non-CF clinical isolates of A.
xylosoxidans, in order to investigate their role in this emerging
pathogen: this is the first report on biofilm formation and motil-
ity of A. xylosoxidans. Genomic fingerprint assessed by RAPD
analysis showed a significant division into two major clusters
(Figure 1). Within such clusters all features considered (BMI,
FEV1%, chronicity, biofilm production, resistance determinants,
motility) were randomly distributed: probably, other features not
taken into account in this study are accountable for cluster forma-
tion. We showed a significant association between RAPD profiles,
FEV1% and biofilm classes, meaning that different CF lung habi-
tats would be able to select particular A. xylosoxidans genomic
variants and biofilm producers. As reported in Table 2, we found
a significant presence of strong biofilm producers within FEV1%
class 1, underlining the influence of biofilm on clinical exacerba-
tions in CF. Biofilm development is a common trait in CF patients
at the surface of airway mucosae (Sibley and Surette, 2011; Sibley
et al., 2011; Bragonzi et al., 2012): bacteria inside biofilms are
well protected, developing antibiotic resistances even by means
of horizontal genetic transfer (HGT) (Molin and Tolker-Nielsen,
2003). Interestingly, all our A. xylosoxidans strains having specific
resistance integrons were strong biofilm producers, supporting
the involvement of HGT in biofilm development (Ghigo, 2001;
Traglia et al., 2012). In this view, the unique environmental A.
xylosoxidans genome sequenced thus far (Strnad et al., 2011)
showed the presence of two large plasmids with resistance genes.
As found in P. aeruginosa, mechanisms other than HGT should
be employed in biofilm formation, such as sub-inhibitory con-
centrations of aminoglycosides involving alterations of c-di-GMP
levels (Hoffman et al., 2005). Interestingly, more than 70% of A.
xylosoxidans strains were resistant to the three aminoglycosides
(gentamicin, amikacin, tobramycin) tested by Vitek 2 instrument
(Figure 2), paving the way of a double strategy (HGT and c-di-
GMP) enrolled by A. xylosoxidans in producing biofilms within
the lung environment to circumvent antibiotic pressure. We had
a high prevalence of patients that underwent colimycin/colistin
usage (41%) before A. xylosoxidans strain isolation, and we
observed only a 20% of resistance to colistin assessed by Vitek2
(Figure 3): this discrepancy should be due to the short time of
exposure (3 months) of the pathogen to the antibiotic. One could
argue that a prolonged exposure should enhance the prevalence
of this resistance determinant within the A. xylosoxidans pop-
ulation, but colimycin/colistin should be a good candidate to
hinder an outbreak. Once established, bacteria are able to swim
within the biofilm itself (Boles and Horswill, 2012; Houry et al.,
2012), enhancing colonization of new patches and nutrient acqui-
sition. Even if around 81% of our A. xylosoxidans strains showed
swimming ability in “Swim plates,” no positive or negative cor-
relation was found with biofilm production assessed by 96-wells
plates (R2 = 5.7∗10−4): thus, further studies will investigate on
A. xylosoxidans motility within established biofilms by means
of fluorescent dyes. This study evidenced how biofilm forma-
tion, antibiotic resistances acquisition, and motility showed by
A. xylosoxidans species could enhance its survival in CF patients’
lung.
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